Technology ID
TAB-2603

Multiplex Assay for Detection of Dengue Virus

E-Numbers
E-148-2013-0
Lead Inventor
Munoz-Jordan, Jorge (CDC)
Co-Inventors
Vergne, Edgardo (CDC)
Santiago, Gilberto (CDC)
Applications
Diagnostics
Therapeutic Areas
Infectious Disease
Development Status
  • In vitro data available
  • In situ data available (on-site)
Lead IC
CDC
ICs
CDC
Dengue virus (DENV) is the cause of dengue illness (dengue fever, dengue hemorrhagic fever, and dengue shock syndrome). CDC researchers have developed a RT-PCR multiplex assay that, prior to sero-conversion, selectively detects dengue virus in biological or other fluid media, such as whole blood, plasma, or serum. The primers and probes from this assay are sufficiently specific to amplify and detect all four DENV serotypes. This FDA-approved technology may provide an improved method for rapid and accurate serotyping of dengue virus in clinical and research settings.
Commercial Applications
  • Rapid, simple and accurate dengue virus (DENV) serotype identification
  • Diagnostic tool for clinical or research settings
Competitive Advantages
  • Increased sensitivity and efficiency compared to current antigen-based assays and single reaction real-time RT-PCR analyses
  • Addresses need for accurate molecular diagnosis of DENV
  • FDA approved technology

Request More Info

Licensing Contact:
Mitzelfelt, Jeremiah
jeremiah.mitzelfelt@nih.gov

Patents

  • US
    Provisional (PRV) 61/554,126
    Filed on 2011-11-01
  • Patent Cooperation Treaty
    (PCT) PCT/US2012/061828
    Filed on 2012-10-25
  • US Patent 9,657,361
    Filed on 2014-04-29
  • US Patent 10,563,269
    Filed on 2017-04-17

Publications

Collaborations

  • Licensing
Date Published